NYR

NYRADA CDI FORUS [NYR]
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Healthcare · ASX Small Cap
$0.5700 +5.6%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when NYR triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track NYR — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Pressing against the upper Bollinger Band — extended and may need to cool off
  • Volume surging at 3.6x normal while price climbs — real buying conviction behind this move
  • Knocking on the door of resistance — if it punches through, things could get interesting
  • Beating the Small Ords index — relative strength of 1.39, so it's outpacing the pack
  • Low cash runway (4 quarters) - dilution risk
  • Very high P/S ratio (56.6x)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 51% over the past year (excluding last month)
  • The bigger volume days are the up days — volume-weighted momentum is positive (4.74%/day)
  • Altman Z-Score distress zone (1.70 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-234%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about NYR
"What's driving NYR today?" "How does NYR compare to peers?" "Key risks for NYR?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Response to ASX Price Query
NONE Change in substantial holding - M Azzi
NONE Notification of cessation of securities - NYR
MEDIUM PROTECT-MI Phase IIa Clinical Trial Update No 2

Recent ASX Announcements

2026-07-15 Response to ASX Price Query PRICE SENSITIVE
2026-07-15 Change in substantial holding - M Azzi
2026-07-05 PROTECT-MI Phase IIa Clinical Trial Update No 2
2026-06-30 Notification of cessation of securities - NYR
2026-06-29 Cleansing Statement

Key Metrics

$134.7M
Market Cap
320K
Avg Volume
3.6x
Vol Ratio
$0.23 — $1.44
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-71.0%
ROE
-234.3%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 52%
LLeader vs LaggardpassRS: 4
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:NYR vs IDTNYR vs ADRNYR vs LDX
Scout Pro — Deeper Analysis for NYR
Try Pro free for 30 days
Share this analysis

Track NYR and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required